Initial treatment
| Agent . | Total n (%) . | Malignancy . | Infection . | Autoimmune . | Idiopathic . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Glucocorticoids | 61 | (98) | 22 | (100) | 21 | (95) | 10 | (100) | 8 | (100) |
| Dexamethasone | 45 | (74) | 18 | (82) | 17 | (81) | 3 | (30) | 7 | (88) |
| Prednisolone∗ | 16 | (26) | 4 | (18) | 4 | (19) | 7 | (70) | 1 | (13) |
| Etoposide | 27 | (44) | 11 | (50) | 9 | (41) | 2 | (20) | 5 | (63) |
| Cyclosporine A | 14 | (23) | 4 | (18) | 5 | (23) | 2 | (20) | 3 | (38) |
| Rituximab | 16 | (26) | 6 | (27) | 10 | (45) | 0 | (0) | 0 | (0) |
| Intravenous immunoglobulins | 19 | (31) | 5 | (23) | 10 | (45) | 0 | (0) | 4 | (50) |
| Cyclophosphamide | 13 | (21) | 8 | (36) | 2 | (9) | 3 | (30) | 0 | (0) |
| Anakinra | 9 | (15) | 1 | (5) | 3 | (14) | 5 | (50) | 0 | (0) |
| Tocilizumab | 2 | (3) | 1 | (5) | 0 | (0) | 1 | (10) | 0 | (0) |
| Alemtuzumab | 1 | (2) | 0 | (0) | 1 | (5) | 0 | (0) | 0 | (0) |
| Ruxolitinib | 1 | (2) | 0 | (0) | 1 | (5) | 0 | (0) | 0 | (0) |
| Cytokine adsorption | 9 | (15) | 4 | (18) | 4 | (18) | 0 | (0) | 1 | (13) |
| Total | 62 | 22 | 22 | 10 | 8 | |||||
| Agent . | Total n (%) . | Malignancy . | Infection . | Autoimmune . | Idiopathic . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Glucocorticoids | 61 | (98) | 22 | (100) | 21 | (95) | 10 | (100) | 8 | (100) |
| Dexamethasone | 45 | (74) | 18 | (82) | 17 | (81) | 3 | (30) | 7 | (88) |
| Prednisolone∗ | 16 | (26) | 4 | (18) | 4 | (19) | 7 | (70) | 1 | (13) |
| Etoposide | 27 | (44) | 11 | (50) | 9 | (41) | 2 | (20) | 5 | (63) |
| Cyclosporine A | 14 | (23) | 4 | (18) | 5 | (23) | 2 | (20) | 3 | (38) |
| Rituximab | 16 | (26) | 6 | (27) | 10 | (45) | 0 | (0) | 0 | (0) |
| Intravenous immunoglobulins | 19 | (31) | 5 | (23) | 10 | (45) | 0 | (0) | 4 | (50) |
| Cyclophosphamide | 13 | (21) | 8 | (36) | 2 | (9) | 3 | (30) | 0 | (0) |
| Anakinra | 9 | (15) | 1 | (5) | 3 | (14) | 5 | (50) | 0 | (0) |
| Tocilizumab | 2 | (3) | 1 | (5) | 0 | (0) | 1 | (10) | 0 | (0) |
| Alemtuzumab | 1 | (2) | 0 | (0) | 1 | (5) | 0 | (0) | 0 | (0) |
| Ruxolitinib | 1 | (2) | 0 | (0) | 1 | (5) | 0 | (0) | 0 | (0) |
| Cytokine adsorption | 9 | (15) | 4 | (18) | 4 | (18) | 0 | (0) | 1 | (13) |
| Total | 62 | 22 | 22 | 10 | 8 | |||||
Only patients who did not receive additional dexamethasone.